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Cancer metastasis is a multistep process associated with the induction of an epithelial-mesenchymal transition (EMT) and
cancer stem cells (CSCs). Although significant progress has been made in understanding the molecular mechanisms
regulating EMT and the CSC phenotype, little is known of how these processes are regulated by epigenetics. Here we
demonstrate that reduced expression ofDNAmethyltransferase 1 (DNMT1) plays an important role in the induction of EMT
and the CSC phenotype by prostate cancer (PCa) cells, with enhanced tumorigenesis and metastasis. First, we observed
that reduction of DNMT1 by 5-azacitidine (5-Aza) promotes EMT induction as well as CSCs and sphere formation in vitro.
Reduced expression of DNMT1 significantly increased PCamigratory potential. We showed that the increase of EMT and
CSC activities by reduction of DNMT1 is associated with the increase of protein kinase C. Furthermore, we confirmed that
silencingDNMT1 is correlatedwith enhancement of the inductionof EMTand theCSCphenotype inPCacells. Additionally,
chromatin immunoprecipitation assay reveals that reduction of DNMT1 promotes the suppression of H3K9me3 and
H3K27me3on theZeb2andKLF4promoter region inPCacells. Critically,we found in ananimalmodel that significant tumor
growth andmore disseminated tumor cells inmost osseous tissueswere observed following injection of 5-Aza pretreated–
PCa cells compared with vehicle-pretreated PCa cells. Our results suggest that epigenetic alteration of histone
demethylation regulated by reduction of DNMT1 may control induction of EMT and the CSC phenotype, which facilitates
tumorigenesis in PCa cells and has important therapeutic implications in targeting epigenetic regulation.
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Prostate cancer (PCa) is the second leading cause of cancer deaths in
American males [1]. Death by PCa in most patients is accompanied
by bone metastasis [2]. Therefore, understanding the mechanisms
underlying the generation of metastasis is crucial for developing future
therapies for cancer treatment. Increasing evidence demonstrates that
cytokines and growth factors from the stromal tumormicroenvironment
are essential in neoplastic progression, which results in deregulation of
normal growth-control mechanisms in the primary tumor sites [3]. In
the prostate, many stromal signals from the tumor microenvironment
contribute to the development of epithelial-mesenchymal transition
(EMT) and cancer stem cell (CSC) phenotypes initiating the metastatic
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EMT creates a self-renewing state (CSCs) that enables redifferentiation
to allow growth and colonization at distant metastatic sites [5–6].
Although many investigations provide important clues as to which
stromal elements and factors lead to tumor progression andmetastasis, the
molecular mechanisms underlying EMT and stemness remain unclear.
Recent studies suggest that epigenetic regulation by DNA
methyltransferases (DNMTs) associates with EMT and CSC
populations within tumors [7–12]. DNA methyltransferase 1
(DNMT1) is a member of the DNA methyltransferase family that
is responsible for maintaining methylation patterns located in CG
dinucleotide-rich regions as well as for transcriptional repression in
cells [13–15]. Aberrant expression of DNMT1 during the G0/G1
phase in the cell cycle may silence tumor suppressors and eliminate
normal arrest signals, leading to the uncontrolled growth in cancer
cells [15,16]. It has been shown that cell cycle regulation of DNMT1
is disrupted in colorectal cancer cells in vivo [17,18] and in other
cancer cells [19,20]. It has also been demonstrated that murine
DNMT1 mRNA is undetectable in growth-arrested BALB/c 3T3
cells but is highly induced at the G1-S boundary of the cell cycle [21]. In
addition, both DNMT1 and p21 have been shown to bind to the
proliferating cell nuclear antigen (PCNA) at the same site in human acute
lymphoblastic leukemia cells, acting as competitive inhibitors [22].
Elevated p21 competes with DNMT1 for PCNA binding in G0/G1
phase, whereas during S phase, elevatedDNMT1 competes with p21 for
binding to PCNA, allowing replication to occur [22]. In PCa, the studies
have shown that high DNMT1 expression is correlated with
advanced-stage cancers [23–26]. Conversely, there is also some evidence
that decreased expression of DNMT1 promotes progression of
early-stage cancers [26]. Importantly, growing evidence suggests that
loss of DNA methylation induces EMT and cancer stem-like
phenotypes, resulting in tumorigenesis and migratory potential and
ultimately increasing tumorigenesis and metastatic capacities [7–10].
In the present study, we explored whether DNMT1 facilitates EMT
induction and the transition of CSCs in PCa cells, which results in
tumorigenesis and metastasis. We demonstrated that reduction of
DNMT1 enhances EMT and CSC phenotypes in association with
protein kinase C (PKC).We also observed that loss of DNMT1 increases
migration of PCa cells. Moreover, we demonstrated in an animal model
that reduction of DNMT1 by pretreatment of 5-azacitidine (5-Aza)
in vitro significantly increases primary tumor growth and bone metastasis
potential of PCa cells. Our results suggest that DNMT1 regulates PCa
metastasis by associating with EMT and CSC properties and has
important implications in targeting of epigenetic therapies.
Materials and Methods
Cell Culture
The human PCa cell lines PC3 and DU145 were obtained from the
American Type Culture Collection (Rockville, MD). The green
fluorescent protein (GFP)–expressing PCa cell lines (PC3GFP and
DU145GFP cells) were established by lentiviral transduction. PCa cells
were grown in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin.
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (QRT-PCR)
Total RNA was extracted from cells using the RNeasy mini kit
(cat. 74104, Qiagen, Valencia, CA) and converted into cDNA using a
First-Strand Synthesis Kit (Invitrogen). Quantitative PCR (real-timePCR) was performed on an ABI 7700 sequence detector using
TaqMan Universal PCR Master Mix according to the directions of
manufacturer (AppliedBiosystems, Foster City, CA). TaqManMGBprobes
(Applied Biosystems) were as follows: DNMT1 (Hs00154749_m1),
E-Cadherin (Hs01013952_m1), N-Cadherin (Hs00169953_m1),
Vimentin (Hs00185584_m1), CD44 (Hs01075861_m1), NFkB1
(HS00765730_m1), Snai l1 (Hs00195591_m1), Snail2
(Hs00950344_m1), Zeb1 (Hs00232783_m1), Zeb2 (Hs00207691_m1),
TGFBR2 (Hs00234253_m1), KLF4 (Hs00358836_m1), and PKCα
(Hs00925193_m1). β-Actin (Hs01060665_g1) was used as internal control
for the normalization of target gene expression.
RNA Interference
PC3 or DU145 cells at 60% confluence were seeded onto 6-well
culture plates. After 24 hours, negative control siRNA (cat. 4390843;
Ambion, Foster City, CA) or DNMT1 siRNA (cat. 439082,
Ambion) with OPTI-MEM (cat. 31985-062; Life Technologies,
Carlsbad, CA) was transfected into PCa cells using Lipofectamine
RNAiMAX (cat. 56532, Life Technologies) according to the
manufacturer's instructions. Transfected cells were incubated at
37°C for 72 hours, and the cells were used in various cell assays.
Silencing was verified by real-time PCR and Western blots.
CSC (CD133+/CD44+ Phenotype) Analysis
PCa cells (PC3 or DU145) (1 × 105) were seeded onto 12-well
culture plates. The cells were treated with vehicle or a demethylating
agent, 5-Aza (0-20 μM) for 4 days. PCa cells were incubated with
PE-anti-CD133 antibody (cat. 130-080-901; Miltenyi Biotec, San
Diego, CA) and APC-anti-CD44 antibody (cat. 559942; BD
Biosciences, San Jose, CA) for 20 minutes at 4°C. The CD133+/
CD44+ fraction was analyzed with a FACS Aria High-Speed Cell
Sorter (BD Biosciences).
Prostatosphere Culture and Assay
The PCa cells (PC3 or DU145) were dissociated to single cells by
standard trypsinization and washed three times with PBS. The cells
were plated in stem cell culture medium (Dulbecco’s modified Eagle’s
medium: F12 plus 10 ng/ml bFGF, 20 ng/ml EGF, 5 mg/ml insulin,
and 0.4% BSA) supplemented with 1% KO serum replacement (cat.
10828-028, Invitrogen) [27] at a density of 1000 cells/ml in
low-attachment 6-well culture plates. Seven-day-old spheres were
enumerated as cell clusters comprised of N30 cells.
Transwell Chemotaxis Assay
PC3 or DU145 cells at 60% confluence (1 × 105) were seeded
onto 24-well culture plates. The cells were treated with vehicle or
5-Aza (5 μM) for 4 days prior to use in Transwell chemotaxis assays.
For these studies, the cells were labeled with 2.5 μg/ml of
carboxyfluorescein diacetate (cat. V12883; Molecular Probes,
Eugene, OR), which facilitated enumeration. The vehicle- or
5-Aza–treated PCa cells were resuspended in serum-free RPMI
1640 and equilibrated for 10 minutes at 37°C. Carboxyfluorescein
diacetate–labeled PCa cells were loaded into the top chambers of
8-μm Transwell microporous membrane 24-well plates (cat. 3422;
Costar Corp, Cambridge, MA). A total of 650 μl of conditioned
medium with chemoattractant CXCL12 (200 ng/ml) (cat.
350-NS-050; R& D System, Minneapolis, MN) was added in the
bottom. The plates were incubated at 37°C. At 3 hours, the number
of cells which had migrated into the lower chambers was determined
by plate reader (Molecular Probes, Eugene, OR).
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Cells, tumor sections, and long-bone sections were used for
immunostaining. Cells were fixed with 10% neutral-buffered formalin
(cat. HT501320, Sigma) and permeabilized with Perm/Wash Buffer
(cat. 554723; BD Biosciences, San Jose, CA). Tumor sections and long
bone sections were blocked, deparaffinized, hydrated, then blocked
with Image-iT FX signal enhancer for 30 minutes, and incubated
for 2 hours at room temperature with primary antibodies combined
with reagents of Zenon Alexa Fluor 488 (green) or 555 (red) labeling
kit (Invitrogen). Human E-Cadherin (1:25 dilution, cat. 610181,
BD Biosciences), N-Cadherin (1:25 dilution, cat. 610921, BD
Biosciences), CD133 (1:50 dilution, cat. 130-090-423; Miltenyi
Biotec, San Diego, CA), CD44 (1:100 dilution, cat. ab6124; Abcam,
Burlingame, CA), DNMT1 (1:50 dilution, cat. ab19905; Abcam,
Cambridge, MA), Zeb2 (1:10 dilution, cat. NBP1-82991; Novus
Biologicals, Littleton, CO), KLF4 (1:50 dilution, cat. ab75486,
Abcam), GFP (1:200 dilution, cat. ab290, Abcam), and (1:100
dilution, cat. ab25117, Abcam) primary antibodies were used. After
washing with PBS, the slides were mounted with ProLong Gold
antifade reagent with DAPI (Invitrogen). Images were taken with a
Olympus FV-500 confocal microscope. Human prostate tissue
microarrays (TMAs) were purchased from US Biomax, Inc. (Rockville,
MD). Tumors were graded using stage progressing system. Co-staining
of anti-human DNMT1 and Zeb2, DNMT1 and N-Cadherin, or
DNMT1 and KLF4 antibodies was applied to TMAs.
Western Blot
PCa cells were cultured in RPMI 1640 with 10% fetal bovine
serum and 1% penicillin/streptomycin. The cells were treated with
vehicle or 5-Aza (5 μM) for 4 days at 37°C. Whole cell lysates were
prepared from cells, separated on 4% to 20% Tris-Glycine gel, and
transferred to PVDF membranes. The membranes were incubated
with 5% milk for 1 hour and incubated with primary antibodies
overnight at 4°C. Primary antibodies used were as follows:
monoclonal anti-DNMT1 (1:1000 dilution, cat. 5032; Cell
Signaling, Danvers, MA), polyclonal anti–E-Cadherin (1:1000
dilution, cat. sc-7870; Santa Cruz, Santa Cruz, CA), monoclonal
anti–N-Cadherin (1:1000 dilution, cat. 610921; BD Transduction
Laboratory, San Jose, CA), polyclonal anti-Zeb2 (1:1000 dilution,
cat. PA5-20980; Thermo Fisher, Waltham, MA), polyclonal
anti-Vimentin (1:1000 dilution, cat. 3932, Cell Signaling), mono-
clonal anti-PKCα (1:1000 dilution, cat. 2056, Cell Signaling),
monoclonal anti-KLF4 (1:1000 dilution, cat. 12173, Cell Signaling),
monoclonal anti-OCT4 (1:1000 dilution, cat. 2750, Cell Signaling),
and monoclonal anti-SOX2 (1:1000 dilution, cat. 3579, Cell
Signaling). Blots were incubated with peroxidase-coupled
anti-mouse IgG secondary antibody (cat. 7076, 1:2000 dilution,
Cell Signaling) or peroxidase-coupled anti-rabbit IgG secondary
antibody (cat. 7074, 1:2000 dilution, Cell Signaling) for 1 hour, and
protein expression was detected with SuperSignal West Dura
Chemiluminescent Substrate (cat. prod. 34075; Thermo Scientific,
Rockford, IL). Membranes were reprobed with monoclonal
anti–β-Actin antibody (1:1000 dilution, cat. 4970, Cell Signaling)
to control for equal loading.
Protein Kinase C (PKC) ELISA
PCa cells (PC3 or DU145) (1 × 105) were seeded onto 12-well
culture plates. The cells were treated with vehicle or 5-Aza (5 μM) for
4 days. Whole cell lysates were prepared to evaluate PKC kinaseactivity by following the directions of the manufacturer (cat.
ADI-EKS-420A; Enzo Life Sciences, Farmingdale, NY). The levels
of PKC kinase activity were normalized to total cell numbers.
In Vitro Chromatin Immunoprecipitation (CHIP)
CHIP assays were performed in vehicle- or 5-Aza (5 μM)–treated
PCa cells (PC3 or DU145) (4 × 106) and siControl- or
siDNMT1-treated PCa cells (PC3 or DU145) (4 × 106) by following
the directions of the manufacturer (cat. 334471, EpiTech CHIP
OneDay Kit, Qiagen). PCa cells were treated with 1% formaldehyde
to cross-link histones to DNA. The cross-linking was stopped by
treating the samples with stop buffer for 5 minutes. The chromatin
was extracted and fragmented by sonication, and the lysate was used
to immunoprecipitation using Protein A + G beads and the following
antibodies; H3K9me3 (cat. GAH-6204, Qiagen), H3K27me3
(cat. GAH-9205, Qiagen), or rabbit control IgG (cat. GAH-9205,
Qiagen). Immunocomplexes were pulled down and washed, and DNA
was isolated to run SYBR qPCR with Zeb2 (assay tile: −0.4 kb; assay
position:−3502) (cat.GPH1021580(−)04A,Qiagen) andKLF4 (assay tile:
−0.4Kb; assay position: −3110) (cat. GPH1026871(−)04A, Qiagen)
specific primers on promoter sites.
Subcutaneous Tumor Growth
All experimental animal procedures were performed in compliance
with the institutional ethical requirements and approved by the
University of Michigan Committee for the Use and Care of Animals.
To evaluate tumor growth, subcutaneous tumors were established.
PCa cells (PC3GFP or DU145GFP) were treated with vehicle or 5 Aza
(5 µM) for four days and then 2 x 105 cells were loaded with Collagen
I (cat. 354236; BD Bioscience, Bedford, MA) and were injected
subcutaneously (s.c.) into 5- to 7-week-old male SCID mice (n =8/
group). The animals were monitored daily. After 4 weeks, the
animals were sacrificed. The tumors and tissue samples were
collected. The tumor volumes and tumor weights were evaluated.
Tumor volumes were calculated using the formula V =(the shortest
diameter) × (the longest diameter) × height. The tumors and femorae
were prepared for histology, and tissue samples were used for tumor
metastasis assays.
In Vivo Metastasis Assay
To evaluatemetastasis, PCa cells labeledwithGFPwere treated in vitro
for 4 days with 5-Aza (5 µM) or vehicle, andwere subsequently implanted
into 5-7 week old male SCID mice. Following tissue harvest, cancer cell
engraftment was assessed by real-time PCR using human Alu TaqMan
probes (F: 5′-CAT GGT GAA ACC CCG TCT CTA-3′, R: 5′-GCC
TCAGCCTCCCGAGTAG-3′, TaqMan probe: 5′-FAM-ATTAGC
CGG GCG TGG TGG CG-TAMRA-3′, Applied Biosystems). The
DNA levels were expressed as relative copies (% control) normalized
against murine β-actin (Mm00607939_s1, Applied Biosystems),
and a standard curve constructed from serial dilutions of a purified
Alu cDNA fragment was cloned by classic PCR. Numerical data were
determined against a standard curve established using murine bone
marrow containing log-fold dilutions of human PCa cells. Positive
and negative controls include tissues obtained from non–PCa-injected
mice or DNA derived directly from PCa cells [28]. Immunohisto-
chemistry for PCa cells in the marrow was also used for metastasis
assays. The numbers of GFP-positive PCa cells were quantified in the
endosteal region of the long bones defined as 10 cell diameters from the
bone surfaces.
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Results are presented as mean ± standard deviation. Distribution
of the data was determined by skewness [29]. Values within a 1.95
(5%) confidence interval were accepted as a normal distribution and
evaluated further using parametric tests for significance. Unpaired
Student's t tests were conducted on data sets of two comparisons, and
significance of data with multiple comparisons was evaluated using an
analysis of variance. Values of P b .05 were considered significant.
Results
Reduction of DNMT1 Promotes EMT Induction in PCa Cells
To explore the role that the epigenetic alteration of DNMT1 plays
in tumor progression, we examined the expression levels of DNMT1
in PCa cells following treatment with 5-Aza. At baseline, high levels of
DNMT1were expressed in human PCa cells. After 4 days of 5-Aza
treatment, DNMT1 expression was significantly decreased in PCa
cells (Figure 1, A and B). These findings suggest that 5-Aza alters the
level of DNMT1 in PCa cells. To further determine if reduction of
DNMT1 expression regulates EMT induction, we first examined the
expression of epithelial and mesenchymal phenotypes in vehicle- or
5-Aza–treated PCa cells by real-time PCR, immunofluorescence
staining, and Western blots. Expression of N-Cadherin and Vimentin
were significantly increased by 5-Aza treatment in PCa cells versus
vehicle-treated PCa cells, indicating the induction of a mesenchymal
phenotype. In sharp contrast, more E-Cadherin was expressed in
vehicle-treated PCa cells versus 5-Aza–treated PCa cells (Figure 1, C–E).
Moreover, expression of mRNA for mesenchymal associated tran-
scription factors Snail1, Snail2, Zeb1, Zeb2, and KLF4 was increased
in 5-Aza–treated PCa cells (Figure 1C). At the protein level, a
significant increase in N-Cadherin, Vimentin, and the Zeb2
transcription factor expression was observed in response to 5-Aza
treatment, whereas E-Cadherin levels decreased (Figure 1E). These
data suggest that reduction of DNMT1 by 5-Aza is associated with an
EMT in PCa cells. To explore the functional role that 5-Aza treatment
has on PCa cells, a migration assay was performed. We observed that
more 5-Aza–treated PCa cells migrated toward the chemoattractant
CXCL12 compared with vehicle-treated PCa cells (Figure 1F). Taken
together, these findings suggest that reduction of DNMT1 expression
by 5-Aza may play a role in PCa migration.
Reduction of DNMT1 Stimulates Transition of CSCs in PCa Cells
The transition to a CSC phenotype is a critical event that enables
redifferentiation to allow growth and colonization at distant
metastatic sites. To expand our understanding of the interplay
between the EMT and CSC activities, we examined the impact of
5-Aza treatment on CSCs. To determine if reduction of DNMT1
expression regulates the CSC phenotype (CD133+/CD44+), PCa
cells were treated with 5-Aza for 4 days, and CSCs were examined by
FACS analysis. A dose-dependent increase in CSCs was identified in
5-Aza–treated PC3 cells (Figure 2A) and DU145 cells (Figure 2B).
Immunofluorescence staining was used to confirm the results obtained
by FACS analysis. As shown in Figure 2C, the CD133/CD44
phenotype was significantly enhanced in PCa cells treated with 5-Aza
compared with PCa cells treated with vehicle. Next, we evaluated the
impact of DNMT1 expression on prostatosphere formation. When
DNMT1 expression is reduced following 5-Aza treatment, a greater
number of prostatospheres formed in culture, and the spheres had a
significantly greater range of sizes (Figure 2, D and E). We furtherexamined whether reduction of DNMT1 by 5-Aza treatment alters
their expression of stem cell–related transcription factors KLF4, OCT4,
and SOX2 in PCa cells. Western blot analysis demonstrates that the
levels of KLF4 and SOX2 were significantly enhanced in the PC3 and
DU145 cells treated with 5-Aza compared with PCa cells treated with
vehicle. OCT4 was decreased in PC3 cells, whereas it was increased in
DU145 cells treated with 5-Aza compared with the cells treated with
vehicle (Figure 2F). Collectively, these results suggest that reduction of
DNMT1 expression plays a crucial role in transition to the CSC
phenotype in PCa cells.
PKCα Associates with DNMT1-Mediated EMT and
CSCs in PCa Cells
The PKC protein family plays a central role in cellular signal
processing. Growing evidence suggests that various isoforms of PKC
participate in the regulation of cell proliferation, differentiation,
survival, and death in normal epithelial cells as well as cancers
[30–33]. It has been demonstrated that the PKCα signaling network
is activated specifically in CSC-enriched populations [31] and that
PKCα suppresses keratinocyte proliferation by increasing p21Cip1
levels by a KLF4 transcription factor–dependent mechanism [32].
Therefore, we evaluated the involvement of PKCα in EMT induction
and transition to a CSC phenotype in 5-Aza–treated PCa cells with
reduced DNMT1 expression. The protein of PKCα was significantly
enhanced in the PCa cells treated with 5-Aza compared with PCa cells
treated with vehicle (Figure 3, A and B). Moreover, we examined
whether the enhancement of PKCα by the reduction of DNMT1
links to inductions of EMT and CSCs by PCa cells. First, we found
that mRNA levels of PKCα were significantly increased in 5-Aza–
treated PCa cells compared with vehicle-treated PCa cells, and
critically, mRNA levels of PKCα were reduced following treatment
with a pan-PKC inhibitor, Go6983 (Figure 3C). Likewise, we also
observed that mRNA levels of Zeb2 and KLF4 transcriptional factors
were correlated to PKCα expression levels in 5-Aza treatment with the
presence or absence of the pan-PKC inhibitor (Figure 3, D and E).
These data indicate that the reduction of DNMT1 by 5-Aza regulates
the EMT and CSC phenotypes in the presence of PKCα expression.
Silencing DNMT1 Is Correlated with EMT Induction and
Stemness in PCa Cells
To further explore whether knockdown of endogenous
DNMT1 regulates induction of EMT and the CSC phenotype,
DNMT1 siRNA was used to silence DNMT1 expression in PCa
cells (PC3siDNMT1 or DU145siDNMT1). mRNA (Figure 4A) and
protein (Figure 4B) levels of DNMT1 were significantly decreased
in PC3siDNMT1 or DU145siDNMT1 cells compared with control PCa
cells (PC3siContol or DU145siControl). To test the correlation of
DNMT1 expression with the EMT induction, EMT markers were
first examined in DNMT1 silenced PCa cells by Western blots.
E-Cadherin was decreased, whereas N-Cadherin and Vimentin were
significantly increased, in PCasiDNMT1 cells compared with PCasiControl
cells (Figure 4C). Moreover, Zeb2 transcription factors were
significantly increased in PCasiDNMT1 cells compared with PCasiControl
cells (Figure 4C). As expected, the silencing DNMT1 in PCa
cells increased the migration (Figure 4D). Regarding CSC transition,
more CSCs were recovered from PCasiDNMT1 cells compared with
PCasiControl cells (Figure 4E). We also examined whether PCasiDNMT1
cells had increased expression of stem cell–related transcription
factors KLF4, OCT4, and SOX2. The levels of KLF4, OCT4, and
Figure 1. Reduction of DNMT1 promotes EMT induction in PCa cells.PCa cells (PC3 or DU145) (1 × 105) were seeded in 6-well culture
plates. The cells were treated by vehicle or 5-Aza (0-20 μM) for 4 days. (A) mRNA levels of DNMT1 expression in vehicle- or 5-Aza (5 μM)–
treated PCa cells (PC3 or DU145) as quantified by real-time PCR. The human prostate epithelial cell RWPE-1 was used as a control. (B)
Protein levels of DNMT1 following vehicle or 5-Aza (5 μM) treatment in PCa cells (PC3 or DU145) as quantified byWestern blots. (C) mRNA
levels of EMT markers in vehicle- or 5-Aza (5 μM)–treated PCa cells (PC3 or DU145) as quantified by real-time PCR. (D) E-Cadherin or
N-Cadherin expression in vehicle- or 5-Aza (5 μM)–treated PCa cells (PC3 or DU145) as detected by immunofluorescence staining. Blue,
DAPI nuclear stain. Bar = 20 μm. (E) EMT markers in vehicle- or 5-Aza (5 μM)–treated PCa cells (PC3 or DU145) as quantified by Western
blots. (F) Migration of vehicle- or 5-Aza (5 μM)–treated PCa cells toward the chemoattractant CXCL12 was performed in Transwell plates.
Percent migration was set at 100% for the initial cell numbers in top chamber. The data in A, C, and F are representative of mean ± SD
(n = 6). P values were calculated by Student's t test.
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PC3siControl cells, and KLF4 expression was significantly increased in
DU145 siDNMT1 cells compared with DU145siControl cells (Figure 4F).
Furthermore, we explored how silencing DMMT1 expression is linked
to PKC expression in PCa cells. There were significantly higher levels of
expression of PKCα in PCa cells (PC3siDNMT1 and DU145siDNMT1)
compared with PCasiControl cells (PC3siControl and DU145siControl)(Figure 4G). We also found that mRNA levels of PKCα were
significantly increased in PCasiDNMT1 cells compared with PC3siControl
cells, and critically, mRNA levels of PKCα were reduced following
treatment with a pan-PKC inhibitor, Go6983 (Figure 4H). We also
observed that mRNA levels of Zeb2 and KLF4 transcriptional factors
were correlated to PKCa expression levels in PCasiDNMT1 cells in the
presence or absence of the pan-PKC inhibitor (Figure 4, I and J). These
Figure 2. Reduction of DNMT1 stimulates transition of CSCs in PCa cells. CSCs (CD133+/CD44+ phenotype) from vehicle- or 5-Aza
(5 μM)–treated (A) PC3 cells or (B) DU145 cells were evaluated by FACS analysis. (C) Coexpression of CD133 (red) and CD44 (green) in
vehicle- or 5-Aza (5 μM)–treated PCa cells as detected by immunofluorescence staining. Blue, DAPI nuclear stain. Bar = 20 μm. (D) In vitro
prostatosphere formation of vehicle or 5-Aza–treated PCa cells (bar = 20-50 μm) and (E) quantification of Figure 2D. (F) Stem cell–related
transcription factors as quantified by Western blots. The data in A, B, and E are representative of mean ± SD (n = 6). P values were
calculated by Student's t test.
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Figure 3. PKCα associates with DNMT1-mediated EMT and CSCs in PCa cells. PCa cells (PC3 or DU145) (1 × 105) were seeded in 6-well
culture plates, and the cells were treated with vehicle or 5-Aza (5 μM) for 4 days.PKC kinase activities as quantified by (A) ELISA (the data
are representative of mean ± SD; Student's t test) and (B) PKCα protein expression as quantified by Western blots. mRNA levels of
(C) PKCα, (D) Zeb2, and (E) KLF4 expression in vehicle or 5-Aza (5 μM) with the presence or absence of a pan-PKC inhibitor, Go6983
(cat. A8343; ApexBio, Houston, TX 77054) treated PCa cells (PC3 or DU145) for 4 days as quantified by real-time PCR. The data in A, C, D,
and E are representative of mean ± SD (n = 3). P values were calculated by Student's t test.
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EMT and CSC phenotypes in the presence of PKCα expression. Taken
together, these findings suggest that silencing DNMT1 is strongly
correlated with enhancement of EMT and CSC phenotypes in the
presence of PKCα expression in PCa cells.
Reduction of DNMT1 Induces Histone Demethylation on the
Zeb2 or KLF4 Promoter in PCa Cells
DNMT1 is necessary to maintain trimethylation of lysine 9 at
histone H3 in pericentromeric regions [34], and loss of DNMT1 by
5-Aza regulates global reduction of di- and trimethylation of histone
H3 lysine 9 (H3K9me2 and H3K9me3) in the many human cancer
cells [34,35]. We examined whether reduction of DNMT1 induces
Zeb2 or KLF4 expression through promoter histone demethylation
of H3K9me3 and H3K27me3 in the 5-Aza– or siDNMT1-treated
PCa cells by CHIP qPCR assays (Figure 5, A and B). We found
that the levels of both silent marks H3K9me3 and H3K27me3
were significantly suppressed in the promotor sites of Zeb2 (−0.4 kb[−3502] sites) or KLF4 (−04 kb [−3110] sites) in DNMT1
downregulated PCa cells, which promote the activation of chromatin,
resulting in the increase of transcription of both Zeb2 and KLF4
(Figure 5, C–G). The data suggest that reduction of DNMT1-
induced histone demethylation on the Zeb2 and KLF4 promoter is
important in the regulation of Zeb2 or KLF4 transcription in EMT or
CSC induction.
Reduction of DNMT1 Stimulates PCa Tumor
Growth and Metastasis
To determine whether reduction of DNMT1 by 5-Aza regulates
tumor growth or bone metastasis by PCa cells, GFP-expressing PCa
cells (PC3GFP or DU145GFP) were pretreated with vehicle or 5-Aza
and injected s.c. into 5- to 7-week-old male SCID mice. After 4
weeks, the mice were sacrificed. Significantly greater tumor volumes
were observed in animals injected with PCa cells pretreated with 5-Aza
in vitro compared with vehicle-pretreated PCa cells (Figure 6, A–F). To
evaluate the metastatic capabilities of DNMT1 inhibited cells, the
Figure 4. Silencing DNMT1 is correlated with EMT induction and stemness in PCa cells. PCa cells (PC3 or DU145) were transiently
transfected with siRNA targeting DNMT1 and cultured for 72 hours. (A) mRNA levels of DNMT1 in control or DNMT1-silenced PCa cells (PC3 or
DU145) asquantifiedby real-timePCR. (B)Protein levelsofDNMT1 incontrolorDNMT1-silencedPCacells (PC3orDU145) asquantifiedbyWestern
blots. (C) EMTmarkers in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified by Western blots. (D) Migration of DNMT1-silenced
PCa cellswas performed by chemotaxis assays. (E) CSC populations (CD133+/CD44+ phenotype) fromcontrol or DNMT1-silenced PCa cells (PC3
orDU145) as evaluated by FACS analysis. The data in A, D, and E are representative ofmean ± SD (n = 6).P valueswere calculated by Student's t
test. (F) Stem cell–related transcription factors in control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified byWestern blots. (G) PKCα in
control or DNMT1-silenced PCa cells (PC3 or DU145) as quantified byWestern blots.mRNA levels of (H) PKCα, (I) Zeb2, and (J) KLF4 expression in
control or DNMT1-silencedPCa cells (PC3orDU145)with the presence or absence of a pan-PKC inhibitor for 3 days as quantified by real-timePCR.
The data in H, I, and J are representative of mean ± SD (n = 3). P values were calculated by Student's t test.
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animals. All animals had significant numbers of DTCs in their bones
following injection of vehicle- or 5-Aza–pretreated PCa cells. Strikingly,
animals receiving 5-Aza–pretreated PCa cells showed a significant
increase of the total DTC load in most osseous tissues compared with
animals injected with vehicle-pretreated PCa cells (Figure 6, G andH).
Critically, significant numbers of DTCs were observed in the bone
marrow near osteoblasts on the bone surface following injection of
5-Aza–pretreated PCa cells (Figure 6, I and J). Together, these dataFigure 5. Reduction of DNMT1 induces histone demethylation of Ze
qPCR assays in 5-Aza– or siDNMT1-treated PCa cells. (B) A scheme sh
site of the human Zeb2 or KLF4 genomic locus. Percent respective inp
CHIP qPCR assays (C) in vehicle- or 5-Aza (5 μM)–treated PCa cells
(PC3, DU145). Percent respective input of H3K9me3 and H3K27me3 le
or 5-Aza–treated PCa cells (PC3, DU145) and (F) in siControl- or
representative of mean ± SD (n = 3). P values are calculated by S
chromatin by histone demethylation of H3K9me3 and H3K27me3 follo
and KLF4 transcription.suggest that reduction of DNMT1 promotes induction of EMT and
CSCs, which plays critical role in PCa growth, cell dissemination,
and metastasis.
Reduction of DNMT1 Associates with Zeb2, N-Cadherin,
or KLF4 in S.C. PCa Tumors andHuman Primary PCa Tumors
To further determine whether EMT or CSC phenotypic changes
by reduction of DNMT1 in in vitromodel reflect to s.c. PCa tumors,
DNMT1 and Zeb2, DNMT1 and N-Cadherin, or DNMT1 andb2 or KLF4 promoter in PCa cells. (A) Experimental design of CHIP
ows the primer sites at the promoter region from transcription start
ut of H3K9me3 and H3K27me3 levels at the Zeb2 genomic locus by
(PC3, DU145) and (D) in siControl- or siDNMT1-treated PCa cells
vels at the KLF4 genomic locus by CHIP qPCR assays (E) in vehicle-
siDNMT1-treated PCa cells (PC3, DU145). The data in C–F are
tudent's t test. (G) A summary diagram shows the activation of
wing 5-Aza or siDNMT1 treatment, resulting in the increase of Zeb2
Figure 6. Reduction of DNMT1 stimulates PCametastasis. GFP-expressing PCa cells (PC3GFP or DU145GFP) pretreatedwith vehicle or 5-Aza
(5 μM) for 4 days were injected s.c. into 5- to 7-week-old male SCIDmice (n = 8/group). After 4 weeks, mice were sacrificed. Tumor growth
was shown in tumors generated with (A–C) PC3 cells or (D–F) DU145 cells. Bar = 10 mm. (G and H) Metastasis was assessed by real-time
PCR for Alu in a number of tissues. * Denotes P b .05 between vehicle- versus 5-Aza–pretreated PCa cells by Student's t test (n = 5). (I) The
GFP-expressing PCa cells were identified in the femorae of SCID mice following s.c. injection. Green arrows identify PCa cells. Red arrows
identify osteoblasts on the bone surface staining positive for CXCL12 expression. Bar = 50 μm. (J) Quantification of I. The numbers of PCa
cells were quantified on the endosteal region of the long bones. Endosteal regions were defined as 10 cell diameters or less from the bone
surfaces. Data are representative of mean ± SD (n = 8/group) on the 5 images per tumor. P values were calculated by Student's t test.
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pretreated PCa cells. High levels of DNMT1 expression were
detected in vehicle-treated PCa tumor cells, whereas more Zeb2,
N-Cadherin, or KLF4 expression was detected in the subset of
DNMT1-reduced cell populations in 5-Aza–pretreated PCa tumor
cells (Figure 7, A and B). To further examine whether these in vitro
and animal results are correlated with human PCa tumors, DNMT1
and Zeb2, DNMT1 and N-Cadherin, or DNMT1 and KLF4
were also co-stained in TMA samples. TMAs from PCa patients
demonstrated that significant levels of DNMT1 expression are
detected in tumor cells compared with normal prostate epithelial
tissues, and that DNMT1 expression is increased in advanced tumor
cells (Figure 7, C and D). We further found that Zeb2, N-Cadherin,
or KLF4 expression was increased in DNMT1-reduced tumor cells in
advanced stages, which correlated with our findings in s.c. animal
models. The data suggest that reduction of DNMT1 is associated
with Zeb2, N-Cadherin, or KLF4, which plays critical role in PCa
tumor growth and metastasis.
Discussion
Epigenetic regulation of genetic programs by DNMTs is associated
with EMT and CSC induction within tumors [7–12]. In this study,
we demonstrate that reduction of DNMT1 stimulates EMT
induction and the transition to a CSC phenotype by PCa cells in
association with PKC expression. Importantly, these changes led to
increased primary tumorigenesis and dissemination in vivo. Together,
these data suggest that reduction of DNMT1 facilitates tumorigenesis
in PCa cells and has important therapeutic implications in targeting
epigenetic regulation.
In the prostate, tumor stroma is known to secrete cytokines and
growth factors, which lay the foundations for self-renewal of CSCs
that lead to tumor progression and EMT for distant metastasis [5,6].
Cytokines and growth factors play an important role in EMT
induction for the development of bone metastasis [3,4,36–38]. For
example, HGF, CXCL12, and TGF-β produced by cancer-associated
fibroblasts (CAFs) have been reported as stimulators of EMT in
cancer cells [3,4,36–38]. CAF-derived CXCL12 triggering CXCR4
expression in cells having undergone an EMT is consistent with the
essential role of CXCL12-CXCR4 signaling during metastasis, as the
level of CXCL12 is elevated in the bone [39]. Recently, we
demonstrated that enhanced levels of stromal CXCL12 by CAFs
promote EMT that supports PCa bone metastasis [3,4]. Furthermore,
transient induction of EMT creates a self-renewing state (CSCs) that
enables redifferentiation to allow growth and colonization at distant
metastatic sites [5,6]. Interestingly, a recent report shows that
CXCL12α stimulates the increase of cardiac stem cell progenitor cells
with c-kit expression through the inhibition of DNMT1 and
DNMT3b expression as well as demethylation of the c-kit gene [40].
In this study, we demonstrated that reduction of DNMT1 induces
EMT and CSCs phenotypes by PCa cells within primary tumors,
resulting in tumorigenesis and metastasis. Elucidating stromal signals
in the tumor microenvironment that are responsible for epigenetic
regulation of EMT and CSC phenotypes may increase the success of
targeted therapies.
Understanding the epigenetic mechanisms of altering DNA
methylation underlying the functional balance of quiescent and
proliferating cancer cells is one of the key pieces of data which is
essential for our ability to better target cancer therapy [9–12].
Deregulated expression of DNMT1 during the cell cycle may beassociated with cellular transformation [15]. In many cancers, high
levels of DNMT1 expression are observed in advanced and metastatic
progression [16–20,23–26]. We also found that high levels of
DNMT1 are expressed in PCa cell lines. It has also been
demonstrated that aberrant expression of DNMT1 eliminates normal
arrest signals, leading to the uncontrolled growth in cancer cells
[13,14]. The DNA methylation inhibitor 5-aza-2′-deoxycytidine
(5-Aza-CdR), a potential anticancer agent, functions in part to reduce
DNMT1 expression by the activation of normal arresting signals,
resulting in antiproliferative effects and antitumorigenic activities. Yet
these actions also lead to the generation of cell cycle arrest signals,
which induce CSCs and EMT phenotypes and ultimately increase
tumorigenesis, and metastatic capacities [9,10].
Many CSCs are not likely cycling and stay in G0, regulated by
arresting signals with the expression of cell cycle inhibitors (e.g., p21
and p27) [41–46]. The epigenetic regulation by DNMTs associates
with CSC populations within tumors [9–12]. CSCs may increase
tumorigenesis through the stem cell processes of self-renewal and
differentiation [9–12]. Further evidence demonstrates that the loss of
pericentromeric DNA methylation with altered DNMT expression is
associated with the stem cell compartment in human glioblastomas
[9], and DNMT1 inhibitor zebularine induces significant levels of
liver CSCs resulting in the increase of highly tumorigenesis [10]. In
addition, 5-Aza treatment increased invasiveness, tumorigenesis, and
metastatic capacities with the upregulation of proinvasive
EMT-associated genes in MCF-7 breast cancer cells [8]. The loss of
DNMT1 dramatically increases migration and invasive potential and
mRNA expression of CDKN3, Claudin-3, and PKC in PCa cells
[23]. Growing evidence shows that the association of DNMT1 with
histone methylation marks. DNMT1 is necessary to maintain
trimethylation of lysine 9 at histone H3 in pericentromeric regions
[34], and loss of DNMT1 by 5-Aza regulates global reduction of di-
and trimethylation of histone H3 lysine 9 (H3K9me2 and
H3K9me3) in the many human cancer cells [34,35]. Here, we
demonstrated that reduction of DNMT1 induced histone demethylation
of H3K9me3 and H3K27me3 on the Zeb2 or KLF4 promoter region,
resulting in the increase of Zeb2 or KLF4 transcription in EMT or CSC
induction of PCa cells. Collectively, reduction of DNMT1 increases
migration in concert with enhanced expression of EMT and CSC
phenotypes in PCa cells. Therefore, careful clarification of the activity of
DNAmethylation inhibitors is important to develop anticancer therapies.
Several mechanisms have been proposed for tumor inhibition by
the DNA methylation inhibitor 5-Aza-CdR, most notably the
demethylation of tumor suppressor genes which results in antitumor
activities. 5-Azacitidine (5-Aza-CdR, decitabine) is currently used for
the treatment of hematologic malignancies, myelodysplastic syn-
drome, and acute myeloid leukemia [47]. Preclinical studies show
that low-dose 5-Aza-CdR is an effective treatment for tumors with
reduced toxicity [47]. There is evidence that estimated plasma levels
(0.04-15 μM) in various doses and schedules of 5-Aza-CdR are
correlated with the clinical responses and remission in hematologic
malignancies [47]. In solid tumors, the clinical response to low-dose
5-Aza-CdR is less clear. One pilot study reported the use of high-dose
5-Aza-CdR (660 mg/m2 as an 8-hour infusion) in stage III/IV non–
small cell lung cancer, which produced an estimated plasma level in
the range of 3 μM [48]. Patients with metastatic malignancy and poor
prognosis are currently recommended for the higher intensive dose of
5-Aza-CdR (60 mg/m2 per hour administered as an 18-hour
infusion/total dose of 1080 mg/m2) with an estimated plasma level
Figure 7. Association of DNMT1 reduction with Zeb2, N-Cadherin, or KLF4 in s.c. PCa tumors and human primary PCa tumors. (A) Zeb2
(green), N-Cadherin (green), or KLF4 (green) expression (white arrow) in DNMT1 (red)-expressing cells in vehicle- or 5-Aza–pretreated s.c.
PCa tumors as detected by immunofluorescence co-staining. Blue, DAPI nuclear stain. Bar = 20 μm. (B) Quantification of A. Data
represent mean ± SD (n = 8/group) (Student's t test). (C) Zeb2 (green), N-Cadherin (green), or KLF4 (green) expression (white arrow) in
DNMT1 (red)-expressing cells in TMA samples from PCa patients as detected by immunofluorescence co-staining. Blue, DAPI nuclear
stain. Bar = 20 μm. TMAs are normal prostate tissue (n = 8), Gleason 6 PCa tissue (n = 9), and Gleason 9 PCa tissue (n = 5). (D)
Quantification of C. Data represent mean ± SD (Student's t test).
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PCa, treatment with 1-hour infusions of 75 mg/m2 5-Aza-CdR every
8 hours for 3 doses was reported to effectively treat the disease in 2 of
12 patients with an evaluable response [49]. 5-Aza-CdR continues to
be an effective agent of growth inhibition and induction of apoptosis
in part by the upregulation of growth arrest signals during the
chemotherapy. Importantly, the developing effective cancer thera-
peutics is required to block primary tumor growth and tumor
metastases to distant organs in solid tumors. Our data showed thatreduction of DNMT1 by 5-Aza treatment increased EMT and CSC
induction, resulting in tumor growth and metastasis which are likely
to be counterproductive when treating PCa. Thus, careful evaluations
and monitoring of patients receiving DNA methylation inhibitors will
be required. Taken together, novel optimization of dose and schedules
for 5-Aza-CdR is needed to establish effective cancer treatments.
Growing attention has focused on the various PKC isoforms
involved in regulation of cell proliferation, differentiation, survival,
and death [30–33]. PKC isoforms are activated by extracellular
Figure 8. Experimental model. Reduction of DNMT1 expression by 5-Aza treatment or silencing of DNMT1 induces EMT and CSC
phenotypes by PCa cells in vitro resulting in tumorigenesis within primary tumor and bone metastasis.Figure 8
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receptors, enzymes, cytoskeletal proteins, and transcription factors
[30–33]. A recent report shows that PKC activation is associated with
the initiation of squamous cell carcinoma formation and progression
to a malignant phenotype [30]. In addition, inhibition of PKCα
reduces tumor-initiating activity and tumor growth of the CSC
enriched populations in vivo [31]. Furthermore, PKCδ suppresses
keratinocyte proliferation by increasing p21Cip1 levels through a
KLF4 transcription factor–dependent mechanism [32], and KLF4 is
required for maintenance of breast CSCs and for cell migration and
invasion [33]. Collectively, these studies strongly support our data
that PKC signals are involved in the development of EMT and CSC
phenotypes.
In summary, this study lays the foundation for a greater
understanding of molecular mechanisms pertaining to DNMT1
function and how it regulates EMT induction and a CSC phenotype,
which facilitates tumorigenesis in PCa cells. Thus, these studies have
important implications for preclinical studies of epigenetic targeted
therapies (Figure 8).
Author Contributions
E. L. and R. S. T. designed experiments. E. L., J. W., K. Y., Y. J.,
F. C. C., A. M. D., and Y. L. performed experiments and analyzed the
data. R. T. F. and K. J. P. discussed the results and gave valuable
critique on the paper. E. L. and R. S. T. wrote the manuscript.
Acknowledgements
Thiswork is directly supported by theNationalCancer Institute (CA093900
to K. J. Pienta and R. S. Taichman; CA163124 to Y. Shiozawa, K. J. Pienta,
and R. S. Taichman; U54CA143803 to K. J. Pienta; CA143055 to K. J.
Pienta), the Department of Defense (W81XWH-11-1-0636 to K. J. Pienta
and R. S. Taichman,W81XWH-15-1-0413 andW81XWH-15-1-0637 to
R. S. Taichman), and the Prostate Cancer Foundation (Y. Shiozawa, K. J.
Pienta, and R. S. Taichman). K.J. Pienta receives support as an American
Cancer Society Clinical Research Professor.
References
[1] Pienta KJ and Esper PS (1993). Risk factors for prostate cancer. Ann Intern Med
118, 793–803.[2] Koutsilieris M (1993). Osteoblastic metastasis in advanced prostate cancer.
Anticancer Res 13, 443–449.
[3] Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ, and Taichman RS
(2010). Characterization of phosphoglycerate kinase-1 expression of stromal cells
derived from tumor microenvironment in prostate cancer progression. Cancer Res
70, 471–480.
[4] Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S,
Lee E, and Sun H, et al (2013). Recruitment of mesenchymal stem cells into
prostate tumors promotes metastasis. Nat Commun 4e1795.
[5] Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, and Shipitsin M, et al (2008). The
epithelial-mesenchymal transition generates cells with properties of stem cells.
Cell 133, 704–715.
[6] Brabletz T (2012). EMT andMET in metastasis: where are the cancer stem cells?
Cancer Cell 22, 699–701.
[7] Wang Y and Shang Y (2013). Epigenetic control of epithelial-to-mesenchymal
transition and cancer metastasis. Exp Cell Res 319, 160–169.
[8] Ateeq B, Unterberger A, Szyf M, and Rabbani SA (2008). Pharmacological
inhibition of DNA methylation induces proinvasive and prometastatic genes
in vitro and in vivo. Neoplasia 10, 266–278.
[9] Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F,
Amatori S, Andreoni F, Magnani M, De Maria R, and Santoni A, et al (2008).
Loss of pericentromeric DNA methylation pattern in human glioblastoma is
associated with altered DNA methyltransferases expression and involves the stem
cell compartment. Oncogene 27, 358–365.
[10] Marquardt JU, Factor VN, and Thorgeirsson SS (2010). Epigenetic regulation of
cancer stem cells in liver cancer: current concepts and clinical implications.
J Hepatol 53(3), 568–577.
[11] Ehrlich M (2009). DNA hypomethylation in cancer cells. Epigenomics 1,
239–259.
[12] Feinberg AP, Ohlsson R, and Henikoff S (2006). The epigenetic progenitor
origin of human cancer. Nat Rev Genet 7, 21–33.
[13] Szyf M and Detich N (2001). Regulation of the DNA methylation machinery
and its role in cellular transformation. Prog Nucleic Acid Res Mol Biol 69, 47–79.
[14] Bigey P, Ramchandani S, Theberge J, Araujo FD, and Szyf M (2000).
Transcriptional regulation of the human DNA methyltransferase (dnmt1) gene.
Gene 242, 407–418.
[15] Szyf M (2001). The role of DNA methyltransferase 1 in growth control.
Front Biosci 6, D599–D609.
[16] Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, and Jones PA (2000).
Differential mRNA expression of the human DNAmethyltransferases (DNMTs)
1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor
cells. Nucleic Acids Res 28, 2108–2113.
[17] el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, and
Baylin SB (1991). High expression of the DNA methyltransferase gene
characterizes human neoplastic cells and progression stages of colon cancer.
Proc Natl Acad Sci U S A 88, 3470–3474.
566 DNMT1 Regulates EMT and CSCs in PCa Metastasis Lee et al. Neoplasia Vol. 18, No. 9, 2016[18] Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR, and
Baylin SB (2000). Increased cytosine DNA-methyltransferase activity during
colon cancer progression. J Natl Cancer Inst 85, 1235–1240.
[19] Nass SJ, Ferguson AT, El-Ashry D, Nelson WG, and Davidson NE (1999).
Expression of DNAmethyl-transferase (DMT) and the cell cycle in human breast
cancer cells. Oncogene 18, 7453–7461.
[20] Wu CT, Wu CF, Lu CH, Lin CC, Chen WC, Lin PY, and Chen MF (2011).
Expression and function role of DNA methyltransferase 1 in human bladder
cancer. Cancer 117, 5221–5233.
[21] Szyf M, Bozovic V, and Tanigawa G (1991). Growth regulation of mouse DNA
methyltransferase gene expression. J Biol Chem 266, 10027–10030.
[22] Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, and Li BF (1997). Human
DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1.
Science 277, 1996–2000.
[23] Yaqinuddin A, Qureshi SA, Qazi R, Farooq S, and Abbas F (2009). DNMT1
silencing affects locus specific DNA methylation and increases prostate cancer
derived PC3 cell invasiveness. J Urol 182, 756–761.
[24] Valdez CD, Davis JN, Odeh HM, Layfield TL, Cousineau CS, Berton TR,
Johnson DG, Wojno KJ, and Day ML (2011). Repression of androgen receptor
transcription through the E2F1/DNMT1 axis. PLoS One 6e25187.
[25] Valdez CD, Kunju L, Daignault S, Wojno KJ, and Day ML (2013). The
E2F1/DNMT1axis is associated with the development of AR negative castration
resistant prostate cancer. Prostate 73, 1776–1785.
[26] Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, and Karpf AR
(2010). Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.
Mol Cell Biol 30, 4159–4174.
[27] Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, and Farrar WL (2010).
Genomic profiling of tumor initiating prostatospheres. BMC Genomics 11, 324.
[28] Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang
J, Mehra R, and Keller ET, et al (2008). In vivo mouse model for human prostate
cancer metastasis. Neoplasia 10(4), 371–380.
[29] Kim HY (2013). Statistical notes for clinical researchers: assessing normal
distribution (2) using skewness and kurtosis. Restor Dent Endod 38(1), 52–54.
[30] Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, and Tennenbaum
T (2007). Protein kinase C family: on the crossroads of cell signaling in skin and
tumor epithelium. J Cancer Res Clin Oncol 133, 793–808.
[31] Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA,
Bierie B, and Guo W, et al (2013). Protein kinase Cα is a central signaling node
and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347–364.
[32] Chew YC, Adhikary G,WilsonGM, Reece EA, and Eckert RL (2011). Protein kinase
C (PKC) delta suppresses keratinocyte proliferation by increasing p21(Cip1) level by a
KLF4 transcription factor–dependent mechanism. J Biol Chem 286, 28772–28782.
[33] Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, and Ai W (2011).
Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem
cells and for cell migration and invasion. Oncogene 30, 2161–2172.
[34] Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, Stockert JC,
Robertson KD, Fuks F, and Esteller M (2004). Human DNA methyltransferase
1 is required for maintenance of the histone H3 modification pattern. J Biol
Chem 279(35), 37175–37184.[35] Jin B, Li Y, and Robertson KD (2011). DNA methylation: superior or
subordinate in the epigenetic hierarchy? Genes Cancer 2(6), 607–617.
[36] Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R,
Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present
in invasive human breast carcinomas promote tumor growth and angiogenesis
through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348.
[37] Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT,
Wang ZC, Richardson AL, and Weinberg RA, et al (2010). Autocrine TGF-beta
and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of
tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A
107, 20009–20014.
[38] Daly AJ, McIlreavey L, and Irwin CR (2008). Regulation of HGF and SDF-1
expression by oral fibroblasts—implications for invasion of oral cancer. Oral
Oncol 44, 646–651.
[39] Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley
LK (2002). Use of the stromal cell–derived factor-1/CXCR4 pathway in prostate
cancer metastasis to bone. Cancer Res 62, 1832–1837.
[40] Chen Z, Pan X, Yao Y, Yan F, Chen L, Huang R, and Ma G (2013). Epigenetic
regulation of cardiac progenitor cells marker c-kit by stromal cell derived
factor-1α. PLoS One 8e69134.
[41] Cheng T (2004). Cell cycle inhibitors in normal and tumor stem cells. Oncogene
23, 7256–7266.
[42] Moore N and Lyle S (2011). Quiescent, slow-cycling stem cell populations in
cancer: a review of the evidence and discussion of significance. J Oncol [pii:
396076].
[43] Wicha MS, Liu S, and Dontu G (2006). Cancer stem cells: an old idea—a
paradigm shift. Cancer Res 66(4), 1883–1890.
[44] Meng E, Mitra A, Tripathi K, FinanMA, Scalici J, McClellan S, Madeira da Silva
L, Reed E, Shevde LA, and Palle K, et al (2014). ALDH1A1 maintains ovarian
cancer stem cell-like properties by altered regulation of cell cycle checkpoint and
DNA repair network signaling. PLoS One 9(9)e107142.
[45] Nguewa P,Manrique I,Díaz R, RedradoM, ParrondoR, Perez-Stable C, andCalvo A
(2014). Id-1B, an alternatively spliced isoform of the inhibitor of differentiation-1,
impairs cancer cell malignancy through inhibition of proliferation and angiogenesis.
Curr Mol Med 14(1), 151–162.
[46] Manrique I, Nguewa P, Bleau AM, Nistal-Villan E, Lopez I, Villalba M,
Gil-Bazo I, and Calvo A (2015). The inhibitor of differentiation isoform Id1b, an
alternatively spliced isoform of the inhibitor of differentiation-1generated by
alternative splicing, maintains cell quiescence and confers self-renewal and cancer
stem cell-like properties. Cancer Lett 356(2 Pt B), 899–909.
[47] Karahoca M and Momparler RL (2013). Pharmacokinetic and pharmacodynamic
analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for
cancer therapy. Clin Epigenetics 5, 3.
[48] Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, and Ayoub
J (1997). Pilot phase I-II study on 5-aza-2'-deoxycytidine (decitabine) in patients
with metastatic lung cancer. Anticancer Drugs 8, 358–368.
[49] Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E,
and Samid D (1998). A phase II study of 5-aza-2'deoxycytidine (decitabine) in
hormone independent metastatic (D2) prostate cancer. Tumori 84, 87–89.
